Literature DB >> 28632968

Perspective on Precision Medicine in Oncology.

Tali M Johnson1.   

Abstract

The topic of precision medicine is increasingly more prevalent in the general medical literature, with oncology research leading the way. Many factors, such as availability of targeted drugs, advances in laboratory science, and improved information systems, converged to make precision medicine research possible on a large scale at the National Cancer Institute. The resultant big data will spur new kinds of research in the decades to come, but until then, all clinicians are challenged to make sense of an overabundance of information when managing individual patients. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  National Cancer Institute; The Cancer Genome Atlas; molecular tumor board

Mesh:

Year:  2017        PMID: 28632968      PMCID: PMC5669055          DOI: 10.1002/phar.1975

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

Review 1.  Next-Generation Sequencing to Guide Clinical Trials.

Authors:  Lillian L Siu; Barbara A Conley; Scott Boerner; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

2.  Molecular analysis for therapy choice: NCI MATCH.

Authors:  Barbara A Conley; James H Doroshow
Journal:  Semin Oncol       Date:  2014-05-22       Impact factor: 4.929

3.  Precision oncology: a strategy we were not ready to deploy.

Authors:  Tito Fojo
Journal:  Semin Oncol       Date:  2016-01-28       Impact factor: 4.929

Review 4.  The Master Protocol Concept.

Authors:  Mary W Redman; Carmen J Allegra
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

5.  Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.

Authors:  Todd C Knepper; Gillian C Bell; J Kevin Hicks; Eric Padron; Jamie K Teer; Teresa T Vo; Nancy K Gillis; Neil T Mason; Howard L McLeod; Christine M Walko
Journal:  Oncologist       Date:  2017-02-08

6.  Toward a Shared Vision for Cancer Genomic Data.

Authors:  Robert L Grossman; Allison P Heath; Vincent Ferretti; Harold E Varmus; Douglas R Lowy; Warren A Kibbe; Louis M Staudt
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

  6 in total
  4 in total

1.  Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis.

Authors:  Xuanfu Chen; Lingjuan Jiang; Wei Han; Xiaoyin Bai; Gechong Ruan; Mingyue Guo; Runing Zhou; Haozheng Liang; Hong Yang; Jiaming Qian
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

Review 2.  Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.

Authors:  Mamello Sekhoacha; Keamogetswe Riet; Paballo Motloung; Lemohang Gumenku; Ayodeji Adegoke; Samson Mashele
Journal:  Molecules       Date:  2022-09-05       Impact factor: 4.927

3.  Impact of an Augmented Reality Navigation System (SIRIO) on Bone Percutaneous Procedures: A Comparative Analysis with Standard CT-Guided Technique.

Authors:  Eliodoro Faiella; Gennaro Castiello; Caterina Bernetti; Giuseppina Pacella; Carlo Altomare; Flavio Andresciani; Bruno Beomonte Zobel; Rosario Francesco Grasso
Journal:  Curr Oncol       Date:  2021-05-08       Impact factor: 3.677

Review 4.  CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer.

Authors:  Sushmaa Chandralekha Selvakumar; K Auxzilia Preethi; Kehinde Ross; Deusdedit Tusubira; Mohd Wajid Ali Khan; Panagal Mani; Tentu Nageswara Rao; Durairaj Sekar
Journal:  Mol Cancer       Date:  2022-03-24       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.